AIC316がFast Track??

昨晩、ちょっとネットを見ていたらビックリするような記事が目に入ってきました！

それが、以下の記事になるんですが、「ひょっとして、AIC316がFDAのFast Trackを受けることができるようになったの？」と思ってしまったんです…！

タイトルから見ても分かると思うんですが、AIC316ではなく、AIC246が対象となっていて（涙）、ヒトサイトメガロウイルス（ヘルペスウイルスの一種だが、性器ヘルペスを起こすHSV2ではない）に対処するためのもののようです…。

まぁ、残念ではありましたが、よく考えてみると、AiCuriusの方もFDAへのFast Track申請方法は十分に理解しているわけで、今後、AIC36をFast Track申請する可能性も十分に考えられると思います。

まずは、希望を持って追い続けるしか無いのかもしれないですね…！


Petition to Congressもこの9月末まで続けるようですので、 是非一度見てみては如何でしょう？

 

AiCuris’ HCMV Drug Letermovir (AIC246) Receives Fast Track from FDA

http://www.bionity.com/en/news/134146/aicuris-hcmv-drug-letermovir-aic246-receives-fast-track-from-fda.html

AiCuris announced that the Food and Drug Administration (FDA) of the United States has granted Fast Track designation for one of the company’s lead drugs, AIC246 (INN: Letermovir), an inhibitor of the human cytomegalovirus (HCMV).

Fast Track designation is an FDA status reserved for products that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs for those conditions. Fast Track designation can also potentially facilitate development and expedite the review and approval process.

“Having obtained Orphan Drug status in the EU, receipt of Fast Track designation for Letermovir in the U.S. is another significant milestone for AiCuris" said Prof. Helga Rübsamen-Schaeff, CEO of AiCuris. “It will hopefully facilitate the regulatory process for this drug and supports our view that Letermovir has the potential to become the treatment of choice for patients at risk to develop severe and life-threatening HCMV disease, such as transplant recipients, newborns, patients in intensive care, certain cancer patients and HIV patients. These patients currently have only limited treatment options, due to the adverse side-effect profiles of existing drugs.”

Letermovir is currently being evaluated in an international Phase IIb trial, which - based on the evaluation of an independent safety monitoring committee - has confirmed a positive safety profile. Results on efficacy from this trial are expected by the end of 2011.